NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy-Reference-Cited by-同舟云学术

NSCLC Patients Harbouring Rare or Complex EGFR Mutations Are More Often Smokers and Might Not Benefit from First-Line Tyrosine Kinase Inhibitor Therapy

Published:2017-11-30 Issue:3 Volume:95 Page:169-176
ISSN:0025-7931
Container-title:Respiration
language:en
Short-container-title:Respiration

Author:

Kauffmann-Guerrero Diego^ORCID,Huber Rudolf Maria,Reu Simone,Tufman Amanda,Mertsch Pontus,Syunyaeva Zulfiya,Jung Andreas,Kahnert Kathrin

Publisher

S. Karger AG

Subject

Pulmonary and Respiratory Medicine

Reference21 articles.

1. Riaz SP, Luchtenborg M, Coupland VH, Spicer J, Peake MD, Moller H: Trends in incidence of small cell lung cancer and all lung cancer. Lung Cancer 2012; 75: 280–284.

2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500.

3. Lindeman NI, Cagle PT, Beasley MB, Chitale DA, Dacic S, Giaccone G, Jenkins RB, Kwiatkowski DJ, Saldivar JS, Squire J, et al: Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thorac Oncol 2013; 8: 823–859.

4. Penzel R, Sers C, Chen Y, Lehmann-Muhlenhoff U, Merkelbach-Bruse S, Jung A, Kirchner T, Buttner R, Kreipe HH, Petersen I, et al: EGFR mutation detection in NSCLC – assessment of diagnostic application and recommendations of the German Panel for Mutation Testing in NSCLC. Virchows Arch 2011; 458: 95–98.

5. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362: 2380–2388.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report;PLOS ONE;2024-06-05

2. An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report;Journal of Medical Case Reports;2024-03-18

3. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study;BMC Cancer;2024-02-19

4. Optimal First-Line Treatment for EGFR-Mutated NSCLC: A Comparative Analysis of Osimertinib and Second-Generation EGFR-TKIs;2024-01-22

5. Rare mutation-dominant compound EGFR-positive NSCLC is associated with enriched kinase domain-resided variants of uncertain significance and poor clinical outcomes;BMC Medicine;2023-02-24